• Je něco špatně v tomto záznamu ?

Serum biomarkers and their relationship to axial spondyloarthritis associated with inflammatory bowel diseases

L. Ondrejčáková, M. Gregová, K. Bubová, L. Šenolt, K. Pavelka

. 2024 ; 23 (3) : 103512. [pub] 20231231

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014565

Spondyloarthritis (SpA) constitute a group of chronic inflammatory immune-mediated rheumatic diseases characterized by genetic, clinical, and radiological features. Recent efforts have concentrated on identifying biomarkers linked to axial SpA associated with inflammatory bowel disease (IBD), offering predictive insights into disease onset, activity, and progression. Genetically, the significance of the HLA-B27 antigen is notably diminished in ankylosing spondylitis (AS) associated with IBD, but is heightened in concurrent sacroiliitis. Similarly, certain polymorphisms of endoplasmic reticulum aminopeptidase (ERAP-1) appear to be involved. Carriage of variant NOD2/CARD15 polymorphisms has been demonstrated to correlate with the risk of subclinical intestinal inflammation in AS. Biomarkers indicative of pro-inflammatory activity, including C-reactive protein (CRP) along with erythrocyte sedimentation rate (ESR), are among the consistent predictive biomarkers of disease progression. Nevertheless, these markers are not without limitations and exhibit relatively low sensitivity. Other promising markers encompass IL-6, serum calprotectin (s-CLP), serum amyloid (SAA), as well as biomarkers regulating bone formation such as metalloproteinase-3 (MMP-3) and Dickkopf-related protein 1 (DKK-1). Additional candidate indicators of structural changes in SpA patients include matrix metalloproteinase-3 (MMP-3), vascular endothelial growth factor (VEGF), tenascin C (TNC), and CD74 IgG. Fecal caprotein (f-CLP) levels over long-term follow-up of AS patients have demonstrated predictive value in anticipating the development of IBD. Serologic antibodies characteristic of IBD (ASCA, ANCA) have also been compared; however, results exhibit variability. In this review, we will focus on biomarkers associated with both axial SpA and idiopathic intestinal inflammation, notably enteropathic spondyloarthritis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014565
003      
CZ-PrNML
005      
20240905133933.0
007      
ta
008      
240725s2024 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.autrev.2023.103512 $2 doi
035    __
$a (PubMed)38168574
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Ondrejčáková, L $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Serum biomarkers and their relationship to axial spondyloarthritis associated with inflammatory bowel diseases / $c L. Ondrejčáková, M. Gregová, K. Bubová, L. Šenolt, K. Pavelka
520    9_
$a Spondyloarthritis (SpA) constitute a group of chronic inflammatory immune-mediated rheumatic diseases characterized by genetic, clinical, and radiological features. Recent efforts have concentrated on identifying biomarkers linked to axial SpA associated with inflammatory bowel disease (IBD), offering predictive insights into disease onset, activity, and progression. Genetically, the significance of the HLA-B27 antigen is notably diminished in ankylosing spondylitis (AS) associated with IBD, but is heightened in concurrent sacroiliitis. Similarly, certain polymorphisms of endoplasmic reticulum aminopeptidase (ERAP-1) appear to be involved. Carriage of variant NOD2/CARD15 polymorphisms has been demonstrated to correlate with the risk of subclinical intestinal inflammation in AS. Biomarkers indicative of pro-inflammatory activity, including C-reactive protein (CRP) along with erythrocyte sedimentation rate (ESR), are among the consistent predictive biomarkers of disease progression. Nevertheless, these markers are not without limitations and exhibit relatively low sensitivity. Other promising markers encompass IL-6, serum calprotectin (s-CLP), serum amyloid (SAA), as well as biomarkers regulating bone formation such as metalloproteinase-3 (MMP-3) and Dickkopf-related protein 1 (DKK-1). Additional candidate indicators of structural changes in SpA patients include matrix metalloproteinase-3 (MMP-3), vascular endothelial growth factor (VEGF), tenascin C (TNC), and CD74 IgG. Fecal caprotein (f-CLP) levels over long-term follow-up of AS patients have demonstrated predictive value in anticipating the development of IBD. Serologic antibodies characteristic of IBD (ASCA, ANCA) have also been compared; however, results exhibit variability. In this review, we will focus on biomarkers associated with both axial SpA and idiopathic intestinal inflammation, notably enteropathic spondyloarthritis.
650    _2
$a lidé $7 D006801
650    12
$a biologické markery $x krev $7 D015415
650    12
$a idiopatické střevní záněty $x krev $x imunologie $x diagnóza $x komplikace $7 D015212
650    _2
$a axiální spondyloartritida $x krev $x diagnóza $7 D000089183
650    _2
$a HLA-B27 antigen $x genetika $x imunologie $7 D015796
650    _2
$a ankylózující spondylitida $x krev $x diagnóza $x imunologie $7 D013167
650    _2
$a leukocytární L1-antigenní komplex $x krev $7 D039841
650    _2
$a C-reaktivní protein $x analýza $x metabolismus $7 D002097
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Gregová, M $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Bubová, K $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: bubova@revma.cz
700    1_
$a Šenolt, L $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: senolt@revma.cz
700    1_
$a Pavelka, K $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00008572 $t Autoimmunity reviews $x 1873-0183 $g Roč. 23, č. 3 (2024), s. 103512
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38168574 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133927 $b ABA008
999    __
$a ok $b bmc $g 2143997 $s 1226431
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 23 $c 3 $d 103512 $e 20231231 $i 1873-0183 $m Autoimmunity reviews $n Autoimmun Rev $x MED00008572
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...